Bruno Steinkraus, PhD, Hummingbird Diagnostics GmbH, Heidelberg, Germany, shares his thoughts on the value of microRNAs as non-invasive biomarkers for the early detection of Alzheimer’s disease (AD). Several groups are working to develop microRNA biomarker panels capable of detecting preclinical and prodromal AD, and distinguishing between other forms of dementia. One of the benefits of microRNAs is that they can provide multiple lines of information. Extracellularly, tissue-specific microRNAs may serve as sensitive plasma markers of tissue injury and intracellularly, they can be a good indicator of immune status. Whole blood samples can therefore capture both of these components. Dr Steinkraus comments on the stability, applicability to high-throughput assessment, and test-retest reliability of microRNAs as biomarkers. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
